Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Lung Cancer

Free Subscription 19.01.2026 5 Ann Thorac Surg 4 BMC Cancer 1 Cancer Cell 1 Cancer Res 7 Chest 2 Clin Cancer Res 1 Clin Exp Metastasis 4 Clin Lung Cancer 2 Eur J Cancer 4 Eur J Cardiothorac Surg 2 Hum Pathol 2 Int J Cancer 4 Int J Radiat Oncol Biol Phys 3 J Clin Oncol 1 J Comput Assist Tomogr 4 J Natl Cancer Inst 1 J Surg Oncol 8 J Thorac Oncol 1 Lancet 1 Lancet Oncol 3 Lung Cancer 1 Lung Cancer (Auckl) 2 Mol Cancer Ther 1 Oncol Rep 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Thorac Surg

1. MADEKA I, Koeneman S, Alaparthi S, Grenda T, et al
   Clinical Outcomes in Non-Small Cell Lung Cancer Among Sustained Adopters of Robotic Thoracic Surgery.
   Ann Thorac Surg. 2026 Jan 14:S0003-4975(26)00012.
   PubMed         Abstract available
   
   
2. MENG S, Che G
   Segmentectomy vs Lobectomy in non-small cell lung cancer patients with occult lymph node metastasis.
   Ann Thorac Surg. 2026 Jan 10:S0003-4975(26)00006.
   PubMed        
   
   
3. LIBERMAN M, Jones DR, Wakelee H, Gao S, et al
   Clinical Characteristics and Surgical Outcomes of Patients Receiving Perioperative Pembrolizumab in KEYNOTE-671.
   Ann Thorac Surg. 2026;121:281-289.
   PubMed         Abstract available
   
   
4. MURAKAMI J, Tanaka T, Shimokawa M, Yoshimine S, et al
   Probiotic Prophylaxis With Clostridium butyricum for Postoperative Infections Following Lung Resection: A Propensity Score-Weighted Analysis.
   Ann Thorac Surg. 2026;121:459-466.
   PubMed         Abstract available
   
   
5. REDDINGTON H, Emmerick I, Crawford A, Briskin C, et al
   Safety and Efficacy of Oncologic Second Pulmonary Resections: A Study of the Society of Thoracic Surgeons General Thoracic Surgery Database.
   Ann Thorac Surg. 2025 Jun 5:S0003-4975(25)00488.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. RAO Y, Rao H, Rao Y, Wu X, et al
   First-line PD-1/PD-L1 inhibitors plus chemotherapy vs. chemotherapy alone in stage IIIB-IV non-squamous NSCLC: an updated meta-analysis of phase 3 RCTs.
   BMC Cancer. 2025;26:46.
   PubMed         Abstract available
   
   
7. ZHANG L, Jia H, Niu B
   Evaluating the efficacy and safety of antibody-drug conjugates in non-small cell lung cancer: a systematic review and meta-analysis.
   BMC Cancer. 2026 Jan 16. doi: 10.1186/s12885-025-15461.
   PubMed        
   
   
8. ZHANG Y, Xie M, Gao J, Ma X, et al
   High endothelial venules abundance in tertiary lymphoid structures: a prognostic biomarker in non-small cell lung cancer with neoadjuvant immunochemotherapy.
   BMC Cancer. 2026 Jan 15. doi: 10.1186/s12885-025-15529.
   PubMed         Abstract available
   
   
9. LIU CY, Lin LF, Tsai CL, Huang TW, et al
   Baseline (1)(8)F-FDG PET/CT radiomics predict early progression and survival in small cell lung cancer.
   BMC Cancer. 2026 Jan 13. doi: 10.1186/s12885-025-15523.
   PubMed         Abstract available
   
   

   
   Cancer Cell

10. HERBRICH S, Chaib M, Anandhan S, Andrewes SW, et al
    TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.
    Cancer Cell. 2026;44:187-202.
    PubMed         Abstract available
    
    

    
    Cancer Res

11. STERN YE, Ghosh P, Peroza J, Solanki HS, et al
    Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors.
    Cancer Res. 2026;86:485-502.
    PubMed         Abstract available
    
    

    
    Chest

12. ODEH B, Pohlman A, Odeh A, Goyal A, et al
    Hospital Variation in Invasive Mediastinal Staging for Patients with Stage I Lung Cancer Treated with Radiation.
    Chest. 2026 Jan 10:S0012-3692(26)00013-9. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
13. ANILE M, Bassi M, Graziano P, Venuta F, et al
    Subsolid Nodule Management: "To Be Or Not To Be" Lung Cancer....
    Chest. 2026;169:e43.
    PubMed        
    
    
14. WANG G, Liu T, Ji W, Shi Z, et al
    Radiographic Phenotypes Should Inform Surgical Decision-Making in 2 to 3 cm Non-Small-Cell Lung Cancer.
    Chest. 2026;169:e42-e43.
    PubMed        
    
    
15. BADE BC, Studts JL
    Association of Shared Decision-Making With Long-Term Adherence to Lung Cancer Screening: If a Decision Is Shared, Does It Last Longer? For Lung Cancer Screening, Maybe Yes.
    Chest. 2026;169:22-23.
    PubMed        
    
    
16. AWIWI MO, Zhang X, Kandemirli VB, Duran C, et al
    Evaluation for Osteoporosis Using Low-Dose Chest CT (LDCT) Obtained for Lung Cancer Screening: A Retrospective Study of 1336 Patients.
    Chest. 2026 Jan 8:S0012-3692(26)00002-4. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    
17. BRUNO DS, Mirsky MM, Donner AL, Kopp SR, et al
    Implementing a Precision Medicine Thoracic Service Using In-House Reflex Testing in a Large Academic-Community Practice.
    Chest. 2026;169:280-290.
    PubMed         Abstract available
    
    
18. SWAMI N, Hong JH, Kho S, Kang HM, et al
    Associations between Prior Lung Diseases and Risk of Lung Cancer in Populations With No Smoking History: A Systematic Review and Meta-Analysis.
    Chest. 2026 Jan 12:S0012-3692(26)00004-8. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

19. PROVENCIO M, Serna-Blasco R, Nadal E, Gonzalez Larriba JL, et al
    Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2026 Jan 15. doi: 10.1158/1078-0432.CCR-25-2958.
    PubMed         Abstract available
    
    
20. PFEIL AJ, Zhang T, Cheng R, Mattar MS, et al
    RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236.
    Clin Cancer Res. 2026 Jan 16. doi: 10.1158/1078-0432.CCR-25-2734.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

21. FICARELLI A, Sassorossi C, Lococo F, Galli A, et al
    What we can learn from the lepidic growth pattern of pulmonary metastases.
    Clin Exp Metastasis. 2026;43:9.
    PubMed        
    
    

    
    Clin Lung Cancer

22. JOSHI U, Ong F, Melzer D, Ma JC, et al
    Optimizing Tarlatamab Delivery in Small Cell and Neuroendocrine Lung Cancer: Real-World Insights into Step-Up Dosing and Prophylactic Tocilizumab Use.
    Clin Lung Cancer. 2025;27:48-58.
    PubMed         Abstract available
    
    
23. TOMASINI P, Juan-Vidal O, Califano R, Lin CC, et al
    Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
    Clin Lung Cancer. 2025;27:38-47.
    PubMed         Abstract available
    
    
24. KUANG Y, Zu K, Xing D, Liu A, et al
    Incidence of Pneumonitis in Asian Patients With Lung Cancer: A Systematic Literature Review and Meta-analysis.
    Clin Lung Cancer. 2025;27:25-37.
    PubMed         Abstract available
    
    
25. SUN J, Dong X, Fu Z, Han S, et al
    Cumulative Incidence and Type-Specific Risk Factors of Pneumonitis After Definitive Chemoradiotherapy With or Without Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025;27:14-24.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

26. AI X, Guo R, Zhang L, Fang J, et al
    Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer.
    Eur J Cancer. 2026;235:116221.
    PubMed         Abstract available
    
    
27. IKEDA S, Ogura T, Misumi T, Nishioka Y, et al
    Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan.
    Eur J Cancer. 2026;235:116232.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

28. JIANG C, Deng C, Deng P, Fu F, et al
    Optimizing mediastinal lymph node dissection by integrating tumor location, consolidation tumor ratio, and size for lung cancer.
    Eur J Cardiothorac Surg. 2026 Jan 13:ezag023. doi: 10.1093.
    PubMed         Abstract available
    
    
29. NAKANISHI Y, Kinoshita F, Matsubara T, Akamine T, et al
    Prognostic Impact of Preoperative Osteopenia for Patients with Resected Non-Small Cell Lung Cancer.
    Eur J Cardiothorac Surg. 2026;68:ezaf481.
    PubMed         Abstract available
    
    
30. ROJAS D, Iquille J, De Latour BR, Pfeuty K, et al
    Surgical Outcomes of Subxiphoid Thoracoscopic Complex Basilar Sublobar Resection Versus Lower Lobectomy: A Single-Centre Retrospective Analysis.
    Eur J Cardiothorac Surg. 2026;68:ezaf482.
    PubMed         Abstract available
    
    
31. NAKAMURA D, Eguchi T, Xing Z, Mishima S, et al
    Video Analysis of Intraoperative Complications and Management in Robotic Lung Segmentectomy.
    Eur J Cardiothorac Surg. 2026;68:ezaf475.
    PubMed         Abstract available
    
    

    
    Hum Pathol

32. NAKAGOMI T, Fujimoto M, Kuriyama S, Hishida T, et al
    Genome-wide DNA methylation profiling of pleomorphic carcinoma of the lung.
    Hum Pathol. 2026;167:106001.
    PubMed         Abstract available
    
    
33. D'AMBROSIO D, Frazzette N, Snuderl M, Jour GK, et al
    Detection of targetable genetic alterations in SMARCA4-deficient neoplasms of the lung - further evidence of a relationship between SMARCA4-deficient undifferentiated tumor and non-small cell carcinoma.
    Hum Pathol. 2026;167:106007.
    PubMed         Abstract available
    
    

    
    Int J Cancer

34. WANG D, Liu T, Yin B, Chang Y, et al
    The lung pre-metastatic niche in osteosarcoma: Mechanism and therapeutic intervention.
    Int J Cancer. 2026;158:1450-1463.
    PubMed         Abstract available
    
    
35. TSURUTA A, Fujimoto M, Hiraoka Y, Taniguchi A, et al
    C-X-C chemokine receptor CXCR4 mediates diurnal changes in the aggregation and dispersion of CD8(+) T cells within the tumor microenvironment.
    Int J Cancer. 2026;158:1740-1754.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

36. SAID BI, Boukhaled GM, Lok BH, Lukovic J, et al
    Cross-Cancer Analysis Reveals a Distinct Pattern of Immune Modulation During Curative Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2026;124:441-450.
    PubMed         Abstract available
    
    
37. WIMMERT L, Gauer T, Dickmann J, Hofmann C, et al
    Dose Reduction in 4-Dimensional Computed Tomography Imaging: Breathing Signal-Guided Deep Learning-Driven Data Acquisition.
    Int J Radiat Oncol Biol Phys. 2026;124:512-521.
    PubMed         Abstract available
    
    
38. MA J, Yu H, Zhang X, Yuan J, et al
    Skull Dosimetry for Mitigating Acute Hematologic Toxicity in NSCLC Patients with Brain Metastases Undergoing Cranial Radiotherapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2025 Dec 24:S0360-3016(25)06623.
    PubMed         Abstract available
    
    
39. ZHAI T, Toprani SM, Dillon-Martin M, Doyle PF, et al
    Telomere Length Dynamics As a Biomarker of Individual Radiation Sensitivity and Pneumonitis in Lung Cancer Patients Receiving Thoracic Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2026 Jan 14:S0360-3016(26)00064.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

40. HIGGINS KA, Hu C, Ross HJ, Jabbour SK, et al
    Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.
    J Clin Oncol. 2026 Jan 13:JCO2501569. doi: 10.1200/JCO-25-01569.
    PubMed         Abstract available
    
    
41. GOSS GD, Darling GE, Westeel V, Nakagawa K, et al
    Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Jan 13:JCO2501828. doi: 10.1200/JCO-25-01828.
    PubMed         Abstract available
    
    
42. KEANE FK, Schoenfeld AJ
    Timing Is of the Essence: Sequencing Immune Checkpoint Blockade and Radiotherapy for Success in Lung Cancer.
    J Clin Oncol. 2026 Jan 14:JCO2502726. doi: 10.1200/JCO-25-02726.
    PubMed        
    
    

    
    J Comput Assist Tomogr

43. LIANG Y, Du J, Wang B, Wang D, et al
    Superior Performance of Synchronized Percutaneous Microwave Ablation and Immediate Percutaneous Biopsy for Highly Suspected Malignant Pulmonary Ground-Glass Nodules.
    J Comput Assist Tomogr. 2026;50:118-125.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

44. SAMET JM, Studts JL
    Lung cancer screening: are race- and risk-aware criteria needed?
    J Natl Cancer Inst. 2026 Jan 13:djaf328. doi: 10.1093.
    PubMed        
    
    
45. BAILEY JT, Chang CJ, Gaston SA, Jackson CL, et al
    Use of hair straighteners and chemical relaxers and incidence of non-reproductive cancers.
    J Natl Cancer Inst. 2026;118:94-101.
    PubMed         Abstract available
    
    
46. BERRINGTON DE GONZALEZ A, Gunter MJ, Schubauer-Berigan MK, Garcia-Closas M, et al
    The multidimensional role of cancer epidemiology in cancer prevention: discovery science and beyond.
    J Natl Cancer Inst. 2026;118:18-25.
    PubMed         Abstract available
    
    
47. WOOSTER M, May M, Agrawal P, Lee J, et al
    The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non-small cell lung cancer.
    J Natl Cancer Inst. 2026;118:49-57.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

48. 
    Correction to "Circulating Levels of Galectin-9 Are a Potential Biomarker of Survival in Advanced Non-Small-Cell Lung Cancer".
    J Surg Oncol. 2026 Jan 12. doi: 10.1002/jso.70188.
    PubMed        
    
    

    
    J Thorac Oncol

49. LEE CK, Lefresne S, Soon YY, Robledo K, et al
    Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trials.
    J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00001.
    PubMed         Abstract available
    
    
50. HAN IS, Ko K, Zou JW, Smith AM, et al
    Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer.
    J Thorac Oncol. 2026 Jan 12:S1556-0864(26)00002.
    PubMed         Abstract available
    
    
51. CARBONE M, Amos C, Attanoos RL, Boeri M, et al
    Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.
    J Thorac Oncol. 2026;21:41-76.
    PubMed         Abstract available
    
    
52. WU H, Fu F, Ye T, Hu H, et al
    Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021).
    J Thorac Oncol. 2026;21:150-159.
    PubMed         Abstract available
    
    
53. KIM YW, Jung S, Kim SJ, Kang HR, et al
    Trajectories of Synchronous Subsolid Nodules in Patients With Resected Subsolid Lung Adenocarcinoma: A Multicenter Cohort Study.
    J Thorac Oncol. 2026;21:174-185.
    PubMed         Abstract available
    
    
54. TAKAHASHI S, Taki T, Nakamura N, Ura A, et al
    Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples.
    J Thorac Oncol. 2026;21:135-149.
    PubMed         Abstract available
    
    
55. BRUNE MM, Roma L, Chijioke O, Alborelli I, et al
    MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC.
    J Thorac Oncol. 2026;21:112-123.
    PubMed         Abstract available
    
    
56. HULBERT A, Tiv R, Cao B, Cesario D, et al
    CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans.
    J Thorac Oncol. 2026;21:124-134.
    PubMed         Abstract available
    
    

    
    Lancet

57. LU S, Wang J, Yang N, Lv D, et al
    Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
    Lancet. 2026 Jan 13:S0140-6736(25)01811-2. doi: 10.1016/S0140-6736(25)01811.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

58. ZHANG L, Zhang X, Wu L, Xing W, et al
    Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2026 Jan 12:S1470-2045(25)00643.
    PubMed         Abstract available
    
    

    
    Lung Cancer

59. MARKS JA, Sweeney K, Elliott A, Gupta B, et al
    SEZ6 expression and lineage plasticity in small cell lung cancer and transformed non-small cell lung cancer.
    Lung Cancer. 2026;213:108913.
    PubMed         Abstract available
    
    
60. GEORGE JE, George PS, Krishna JKM, Mathew A, et al
    Corrigendum to "Global trends in lung cancer incidence and mortality by age, gender and morphology and forecast: A bootstrap-based analysis". [Lung Cancer 205 (2025) 108626].
    Lung Cancer. 2026 Jan 11:108909. doi: 10.1016/j.lungcan.2026.108909.
    PubMed        
    
    
61. WANG Y, Zhang L, Zhan J, Wen L, et al
    Comparative efficacy and safety of post-TKI treatments for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and network meta-analysis.
    Lung Cancer. 2026;212:108914.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

62. SCHRAPS N, Reck M, Hantzsch-Kuhn B, Olchers T, et al
    Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer.
    Lung Cancer (Auckl). 2026;17:1-10.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

63. GERA N, Fitzgerald KM, Ramesh V, Patel P, et al
    MYTX-011: A pH-Dependent Anti-c-MET Antibody-Drug Conjugate Designed for Enhanced Payload Delivery to c-MET-Expressing Tumor Cells.
    Mol Cancer Ther. 2024;23:1282-1293.
    PubMed         Abstract available
    
    
64. NGUYEN T, Carrieri FA, Connis N, Lafargue A, et al
    TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy.
    Mol Cancer Ther. 2024;23:1201-1211.
    PubMed         Abstract available
    
    

    
    Oncol Rep

65. MA H, Li L, Jiao C, Cheng Y, et al
    

    Immunotherapy after EGFR?TKI treatment in advanced non?small cell lung cancer: Current status and future perspectives (Review)

    .
    Oncol Rep. 2026;55:44.
    PubMed         Abstract available
    
    

    
    PLoS One

66. LI C, Jiang J, Ma Z, Yu Z, et al
    Adaptive and migration-enhanced tree seed algorithm for multi-threshold CT image segmentation and lung cancer recognition.
    PLoS One. 2026;21:e0333304.
    PubMed         Abstract available
    
    
67. LI Q, Zhang J, Meng S, Tian F, et al
    Correlation between self-regulatory fatigue and physical activity in lung cancer patients undergoing comprehensive treatment.
    PLoS One. 2026;21:e0341077.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.